WO2001009131A1 - Derives d'azaindolizinone et ameliorants de la fonction cerebrale contenant lesdits derives en tant que principes actifs - Google Patents
Derives d'azaindolizinone et ameliorants de la fonction cerebrale contenant lesdits derives en tant que principes actifs Download PDFInfo
- Publication number
- WO2001009131A1 WO2001009131A1 PCT/JP2000/005034 JP0005034W WO0109131A1 WO 2001009131 A1 WO2001009131 A1 WO 2001009131A1 JP 0005034 W JP0005034 W JP 0005034W WO 0109131 A1 WO0109131 A1 WO 0109131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pyridin
- imidazo
- melting point
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to an azindridinone derivative and a brain function improving agent containing the same as an active ingredient.
- the present invention provides a compound represented by the general formula (I):
- R is a hydrogen atom, a halogen atom, C alkyl
- R 2 is a hydrogen atom, C, -C 6 alkyl, C, -C 6 alkoxy, hydroxy, amino, genogen, amino, acetylamino, benzylamino, trifluoromethyl or -0- (CH 2 ) n -R 5 (R 5 is vinyl, C 3 - C s cycloalkyl, phenyl, n represents 0 or 1),
- R 4 is - C 6 alkyl or - CH (R 7) - R 6 (R fi vinyl, Echiniru, phenyl (C, - C fi alkyl, C fi alkoxy, human Dorokishi 1-2 halogens nuclear, di - Arukiruamino, Shiano, nitro, carboxy, optionally substituted by phenyl), phenethyl, pyridyl, thienyl, furyl, R 7 is a hydrogen atom, - (: 6 alkyl) and or R 3 represents a R 4 is bonded to form indane or dihydrophenalene.]
- Dementia is a condition in which the brain's function, once acquired, is continuously impaired, impairing memory, judgment and thinking, and causing problems in normal social life.
- Alzheimer's disease, cerebrovascular dementia, and a mixture of both types account for 80% to 90% of the diseases that cause senile dementia, and the core symptom is memory impairment.
- choline acetyltransferase an acetylcholine synthase
- cognitive function as seen by mental test score correlates with decreased cerebral cortical ChAT activity [Perry et al., Br. Med. J. 25, 1457-1459 (1978)].
- the present inventors have conducted intensive studies to obtain a compound having an improving effect on cognitive dysfunction through the central nervous system, particularly the cholinergic nervous system, and as a result, the compound represented by the general formula (I) is obtained.
- the present invention has been completed by finding that an azadoindolinone derivative has a significant anti-amnesic effect on scopolamine-induced amnesia in rats.
- (: C 6) means a group having 1 to 6 carbon atoms without limitation.
- C 3 -C 8 means a group having 3 to 8 carbon atoms without limitation.
- -Alkyl means a straight or branched chain of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, n-pentyl, n-hexyl, etc. Alkyl group.
- rc,- ⁇ alkoxy includes straight or branched chains such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, ten-butoxy, sec-butoxy, n-pentyloxy, n-hexyloxy, etc. Alkoxy group.
- C 3 -C 8 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Halogen atom includes fluorine, chlorine, bromine and iodine.
- Examples of the compound of the present invention include the following compounds, but the present invention is not limited to these compounds.
- the compound (I) of the present invention has an asymmetric carbon atom in its structure, an isomer derived from the asymmetric carbon atom and a mixture thereof (racemic form) exist, and each of them is a compound of the present invention. Shall be included.
- the compounds of the present invention may be in the form of acid addition salts as pharmaceutically acceptable salts.
- Suitable acid addition salts include inorganic acid salts such as hydrochloride, sulfate, For organic acid salts such as hydrobromide, nitrate, phosphate etc., for example, acetate, oxalate, propionate, glycolate, lactate, pyruvate, malonate, succinate, maleic acid Salts, fumarate, malate, tartrate, citrate, benzoate, cinnamate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, salicylate, and the like.
- the compound of the present invention represented by the general formula (I) is a novel compound, and is produced by applying the method of Kakehi et al. That is, as shown in the following reaction formula, starting from a pyridinium bromide of the general formula (II) as a starting material, 1,8-diazabicyclo [5,4,0] -7-pandecene, sodium ethoxide, hydroxyl It can be produced by reacting with an aralkyl halide of the general formula (III) in the presence of a base such as sodium chloride.
- R, R 2 , R 3 , R 4 , R fi and R 7 are the same as defined above, and R 8 is a hydrogen atom.
- dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile, methanol, ethanol and the like can be used as the solvent.
- the compound of the present invention thus obtained can be separated and purified by a usual method, for example, extraction, concentration, neutralization, filtration, recrystallization, column chromatography and the like.
- the acid addition salt of the compound of the general formula (I) of the present invention can be produced by various methods known in the art. Suitable acids used are, for example, hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, phosphoric acid, etc. for inorganic acid salts, and acetic acid, oxalic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid for organic acid salts.
- succinic acid maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- test Examples 1) and 2) correspond to the compound numbers in Examples described later.
- anti-dementia substances were used as comparative compounds.
- the passive avoidance learning experiment device consists of a light room and a dark room, both of which are separated by a wall with an entrance.
- Floor made of stainless steel The wiring for energization is given only to the dalid in the dark room.
- one rat was placed in the light room to acclimate to the passive avoidance learning device, and preliminary training was performed in which the rats were allowed to move freely in the device for 3 minutes.
- mice Male ICR strain mice (6 weeks old, 27.9 ⁇ 0.4 g) were subjected to the experiment. Food and water were available ad libitum. However, fasting was performed for 17 hours before administration of the test compound and for 4 hours after administration. The test compound was suspended in 1% hydroxypropylcellulose (HPC) and orally administered. Symptoms were frequently observed up to 6 hours after administration of the test compound, and thereafter, once a day for 14 days.
- HPC hydroxypropylcellulose
- Compound 8 and Compound 10 were used as test compounds, and no deaths were observed in either case after oral administration of 2, OOO mg / kg.
- the compound (I) of the present invention has a very good separation between the effect on the central nervous system and the effect on the peripheral nerve, and at a dose (0.01 to 10 mg / kg) showing an antiamnestic effect in rats, it has a convulsive effect. It has no peripheral effects such as salivation and diarrhea, and has a significant effect by oral administration. Therefore, it is useful as a brain function improving agent for mammals including humans.
- Useful target diseases of the compounds of the present invention include, for example, senile dementia, Alzheimer's disease, Parkinson's disease and other central nervous diseases, and can be used for the prevention or treatment of these diseases.
- the compound of the present invention can be administered orally or parenterally.
- oral administration form examples include tablets, coated tablets, powders, granules, capsules, microcapsules, syrups and the like.
- dosage forms for oral administration injections (including freeze-dried injections to be dissolved and used at the time of use), suppositories and the like can be used.
- compositions require the use of pharmaceutically acceptable excipients, binders, lubricants, Agents, suspending agents, emulsifiers, preservatives, stabilizers and dispersants such as lactose, sucrose, starch, dextrin, crystalline cellulose, kaolin, calcium carbonate, talc, magnesium stearate, distilled water or saline. It is performed using.
- the dosage varies depending on the patient's condition, age, weight, etc., but 0.1 to 50 mg per day for adults can be administered in 1 to 3 divided doses.
- the compound of the present invention has a very good effect on the central nervous system and the effect on the peripheral nerves, and exhibits a remarkable anti-amnesic effect when administered to a rat. Therefore, the compound improves the brain function of mammals including humans, such as senile dementia. It can be applied to the prevention or treatment of Alzheimer's disease, Parkinson's disease and other central nervous system diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001514334A JP4530597B2 (ja) | 1999-07-30 | 2000-07-28 | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 |
DK00948260T DK1219621T3 (da) | 1999-07-30 | 2000-07-28 | Azaindolizinonderivater og cerebral funktionsforbedrende midler indeholdende disse som den aktive bestanddel |
EP00948260A EP1219621B1 (en) | 1999-07-30 | 2000-07-28 | Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components |
US10/030,159 US6635652B1 (en) | 1999-07-30 | 2000-07-28 | Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient |
CA2387719A CA2387719C (en) | 1999-07-30 | 2000-07-28 | Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components |
AU61803/00A AU766122B2 (en) | 1999-07-30 | 2000-07-28 | Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components |
AT00948260T ATE252580T1 (de) | 1999-07-30 | 2000-07-28 | Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten |
DE60006145T DE60006145T2 (de) | 1999-07-30 | 2000-07-28 | Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21700299 | 1999-07-30 | ||
JP11/217002 | 1999-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001009131A1 true WO2001009131A1 (fr) | 2001-02-08 |
Family
ID=16697291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005034 WO2001009131A1 (fr) | 1999-07-30 | 2000-07-28 | Derives d'azaindolizinone et ameliorants de la fonction cerebrale contenant lesdits derives en tant que principes actifs |
Country Status (12)
Country | Link |
---|---|
US (1) | US6635652B1 (ja) |
EP (1) | EP1219621B1 (ja) |
JP (1) | JP4530597B2 (ja) |
KR (1) | KR100738136B1 (ja) |
CN (1) | CN1179962C (ja) |
AT (1) | ATE252580T1 (ja) |
AU (1) | AU766122B2 (ja) |
CA (1) | CA2387719C (ja) |
DE (1) | DE60006145T2 (ja) |
DK (1) | DK1219621T3 (ja) |
ES (1) | ES2209927T3 (ja) |
WO (1) | WO2001009131A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008047952A2 (en) | 2006-10-13 | 2008-04-24 | Zenyaku Kogyo Kabushikikaisha | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
WO2009107401A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushikikaisha | Kit, composition, product or medicament for treating cognitive impairment |
JP2012512173A (ja) * | 2008-12-15 | 2012-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141579B2 (en) * | 2001-01-30 | 2006-11-28 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient |
EP2502925A1 (en) * | 2004-10-27 | 2012-09-26 | Janssen Pharmaceutica NV | Pyridine imidazoles and aza-indoles as progesterone receptor modulators |
WO2008112641A2 (en) * | 2007-03-09 | 2008-09-18 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
EP2413929A4 (en) * | 2009-04-02 | 2012-10-10 | Zenyaku Kogyo Co Ltd | PROCESS FOR TREATING COGNITIVE IMPAIRMENT |
WO2010120872A2 (en) * | 2009-04-14 | 2010-10-21 | Kim Nicholas Green | Method of decreasing pro-adam10 secretase and/or beta secretase levels |
JP2012526818A (ja) * | 2009-05-11 | 2012-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ユビキチン化タンパク質レベルの減少方法 |
AU2022275939A1 (en) * | 2021-05-19 | 2023-11-16 | Amyriad Pharma, Inc. | Method of treating alzheimer's disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492695A (en) * | 1982-04-21 | 1985-01-08 | Synthelabo | Therapeutically useful imidazo[1,2-a]pyridine derivatives |
US4514415A (en) * | 1981-10-28 | 1985-04-30 | Ciba Geigy Corporation | Benzofuran-2(3H)-ones used as anti-inflammatory agents |
US4760083A (en) * | 1986-04-10 | 1988-07-26 | E. I. Dupont De Nemours & Company | 3,3-disubstituted indolines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2585086B2 (ja) * | 1988-12-28 | 1997-02-26 | 大鵬薬品工業株式会社 | ジアザビシクロアルカン誘導体 |
US5464843A (en) * | 1992-06-23 | 1995-11-07 | G.D. Searle & Co. | Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury |
-
2000
- 2000-07-28 EP EP00948260A patent/EP1219621B1/en not_active Expired - Lifetime
- 2000-07-28 WO PCT/JP2000/005034 patent/WO2001009131A1/ja active IP Right Grant
- 2000-07-28 JP JP2001514334A patent/JP4530597B2/ja not_active Expired - Fee Related
- 2000-07-28 ES ES00948260T patent/ES2209927T3/es not_active Expired - Lifetime
- 2000-07-28 DK DK00948260T patent/DK1219621T3/da active
- 2000-07-28 DE DE60006145T patent/DE60006145T2/de not_active Expired - Lifetime
- 2000-07-28 US US10/030,159 patent/US6635652B1/en not_active Expired - Lifetime
- 2000-07-28 CA CA2387719A patent/CA2387719C/en not_active Expired - Lifetime
- 2000-07-28 CN CNB008137390A patent/CN1179962C/zh not_active Expired - Fee Related
- 2000-07-28 KR KR1020027001338A patent/KR100738136B1/ko active IP Right Grant
- 2000-07-28 AU AU61803/00A patent/AU766122B2/en not_active Ceased
- 2000-07-28 AT AT00948260T patent/ATE252580T1/de not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4514415A (en) * | 1981-10-28 | 1985-04-30 | Ciba Geigy Corporation | Benzofuran-2(3H)-ones used as anti-inflammatory agents |
US4492695A (en) * | 1982-04-21 | 1985-01-08 | Synthelabo | Therapeutically useful imidazo[1,2-a]pyridine derivatives |
US4760083A (en) * | 1986-04-10 | 1988-07-26 | E. I. Dupont De Nemours & Company | 3,3-disubstituted indolines |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008047952A2 (en) | 2006-10-13 | 2008-04-24 | Zenyaku Kogyo Kabushikikaisha | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
JP2008094795A (ja) * | 2006-10-13 | 2008-04-24 | Zenyaku Kogyo Kk | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
WO2008047951A3 (en) * | 2006-10-13 | 2009-02-05 | Zenyaku Kogyo Kk | An alzheimer' s disease progression inhibitor containing heterocyclic compound |
WO2008047952A3 (en) * | 2006-10-13 | 2009-04-16 | Zenyaku Kogyo Kk | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
EP2388002A3 (en) * | 2006-10-13 | 2012-01-25 | Zenyaku Kogyo Kabushikikaisha | Antidepressant containing heterocyclic compound having specific structure |
KR101156412B1 (ko) | 2006-10-13 | 2012-06-13 | 젠야쿠코교가부시키가이샤 | 특정 구조를 갖는 복소환 화합물을 함유하는 항우울제, 신경 보호제, 아밀로이드 β 침착 억제제 또는 노화 억제제 |
WO2009107401A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushikikaisha | Kit, composition, product or medicament for treating cognitive impairment |
JP2011513200A (ja) * | 2008-02-28 | 2011-04-28 | 全薬工業株式会社 | 認知機能障害を治療するためのキット、組成物、製品もしくは医薬 |
EA023751B1 (ru) * | 2008-02-28 | 2016-07-29 | Зеняку Когио Кабусикикайся | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности |
JP2012512173A (ja) * | 2008-12-15 | 2012-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2209927T3 (es) | 2004-07-01 |
CA2387719C (en) | 2010-04-27 |
DE60006145D1 (de) | 2003-11-27 |
CN1179962C (zh) | 2004-12-15 |
CA2387719A1 (en) | 2001-02-08 |
AU766122B2 (en) | 2003-10-09 |
CN1377351A (zh) | 2002-10-30 |
KR100738136B1 (ko) | 2007-07-10 |
EP1219621A1 (en) | 2002-07-03 |
DK1219621T3 (da) | 2004-02-02 |
DE60006145T2 (de) | 2004-06-09 |
AU6180300A (en) | 2001-02-19 |
EP1219621B1 (en) | 2003-10-22 |
ATE252580T1 (de) | 2003-11-15 |
JP4530597B2 (ja) | 2010-08-25 |
US6635652B1 (en) | 2003-10-21 |
KR20020016931A (ko) | 2002-03-06 |
EP1219621A4 (en) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4790703B2 (ja) | 環式化合物 | |
US7767824B2 (en) | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | |
TWI397530B (zh) | 經取代的三唑并吡啶及其類似物 | |
JP5524071B2 (ja) | 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト | |
TWI441635B (zh) | 含有具特殊結構雜環化合物於抑制澱粉狀蛋白β沉澱的阿茲海默氏症發展抑制劑之用途 | |
JPH11501925A (ja) | 置換N−アリールメチルおよびヘテロシクリルメチル−1H−ピラゾロ〔3,4−b〕キノリン−4−アミン並びにそれらを含有する組成物 | |
JP4530597B2 (ja) | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 | |
AU2009259121B2 (en) | Novel derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | |
SI9400120A (en) | Benzylimidazopyridine derivative as angiotensin ii receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020027001338 Country of ref document: KR Ref document number: 10030159 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 61803/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2387719 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000948260 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027001338 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008137390 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000948260 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000948260 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 61803/00 Country of ref document: AU |